WOW. EUA for no efficacy and leronlimab sits on the shelf. FDA is shameful. I wonder if a revocation is forthcoming.

---

CONCLUSIONS
No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535. opens in new tab.)

https://www.nejm.org/doi/full/10.1056/NEJMoa2031304